Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $6.7 million.

  • Immunome's Change in Accured Expenses rose 1340.29% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 10721.76%. This contributed to the annual value of $13.6 million for FY2024, which is 210684.04% up from last year.
  • Immunome's Change in Accured Expenses amounted to $6.7 million in Q3 2025, which was up 1340.29% from $619000.0 recorded in Q2 2025.
  • Over the past 5 years, Immunome's Change in Accured Expenses peaked at $6.9 million during Q2 2024, and registered a low of -$8.5 million during Q1 2025.
  • Its 3-year average for Change in Accured Expenses is $1.2 million, with a median of $669000.0 in 2024.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 51853.42% in 2024, then crashed by 137369.21% in 2025.
  • Immunome's Change in Accured Expenses (Quarter) stood at $2.1 million in 2023, then plummeted by 97.92% to $43000.0 in 2024, then surged by 15562.79% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $619000.0 for Q2 2025, and -$8.5 million during Q1 2025.